Yankaskas J R, Aris R
Cystic Fibrosis/Pulmonary Research and Treatment Center, and Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina, Chapel Hill 27599-7248, USA.
Curr Opin Pulm Med. 2000 Nov;6(6):551-7. doi: 10.1097/00063198-200011000-00016.
Lung transplantation has become an accepted treatment for respiratory failure due to cystic fibrosis (CF). Effective means of patient selection, surgical technique, immunosuppression, and post-transplant management permit survival as good as that of transplant patients with other diseases. The new lungs do not acquire the CF ion transport abnormalities but are subject to the usual post-transplant complications. CF problems in other organ systems persist and may be worsened by some of the immunosuppressive regimens. Prolonged survival increases the risk of age-related CF and other complications. Effective medical management requires expert knowledge of CF and lung transplantation and of how their problems interact, and good communications among the participating care teams.
肺移植已成为治疗囊性纤维化(CF)所致呼吸衰竭的一种公认疗法。有效的患者选择方法、手术技术、免疫抑制及移植后管理可使患者的生存率与患有其他疾病的移植患者相当。新肺不会出现CF离子转运异常,但会出现常见的移植后并发症。其他器官系统的CF问题依然存在,并且某些免疫抑制方案可能会使其恶化。生存期延长会增加与年龄相关的CF及其他并发症的风险。有效的医疗管理需要具备CF和肺移植方面的专业知识,了解它们的问题如何相互作用,并且参与治疗的团队之间要进行良好的沟通。